Literature DB >> 30458454

The Spleen Promotes the Secretion of CCL2 and Supports an M1 Dominant Phenotype in Hepatic Macrophages During Liver Fibrosis.

Liang Li1,2, Wei Wei1,2, Zhenzhen Li1,2, Haiyan Chen1, Yu Li1,2, Wei Jiang1,2, Weisan Chen1,3, Guangyao Kong4,5, Jun Yang1,2, Zongfang Li1,2.   

Abstract

BACKGROUND/AIMS: Liver fibrosis is a complex process of tissue remodeling in response to injury. Hepatic macrophages have been identified as a key player in this process. As the largest lymphoid organ in the body, the spleen exerts both local and systemic effects on immune cell response. Splenectomy can improve hepatic function during the treatment of liver cirrhosis. However, whether the spleen influences disease progression through the modulation of hepatic macrophages remains unclear.
METHODS: We examined ex vivo hepatic macrophage responses from splenectomized or sham operated rats and performed splenocyte adoptive transfer studies, in combination with in vivo CCL2 blockade, in splenectomized or sham operated rats.
RESULTS: We found that splenectomy reduced fibrosis severity and monocyte/ macrophage infiltration within the injured liver. Splenectomy also reduced secretion of the monocyte chemokine CCL2 by hepatic macrophages. Ex vivo, splenocytes, especially splenic macrophages, promoted CCL2 secretion via upregulation of SOCS3 signaling in hepatic macrophages. Migration of splenic monocytes in response to conditioned medium from hepatic macrophages was inhibited by the blockade of SOCS3-CCL2-CCR2 signaling. Splenectomy also attenuated the establishment of an M1-dominant hepatic macrophage phenotype whilst the adoptive transfer of splenocytes could partly reverse this effect and exacerbate fibrosis. However, CCL2 blockade following adoptive splenocyte transfer restored the protective effects of splenectomy.
CONCLUSION: Our study demonstrates that splenic macrophages can promote hepatic macrophage secretion of CCL2, which in turn facilitates monocyte recruitment and the establishment of an M1-dominant hepatic macrophage phenotype, and thus increase the severity of liver fibrosis.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  CCL2; Liver fibrosis; Macrophage; Phenotype; SOCS3; Spleen

Mesh:

Substances:

Year:  2018        PMID: 30458454     DOI: 10.1159/000495276

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  17 in total

1.  Salt-sensitive increase in macrophages in the kidneys of Dahl SS rats.

Authors:  Daniel J Fehrenbach; Justine M Abais-Battad; John Henry Dasinger; Hayley Lund; David L Mattson
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-19

Review 2.  Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting.

Authors:  Arjuna Singanayagam; Evangelos Triantafyllou
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 7.561

3.  2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.

Authors:  Eunsun Park; Kyung-Hee Song; Darong Kim; Minyoung Lee; Nguyen Van Manh; Hee Kim; Ki Bum Hong; Jeewoo Lee; Jie-Young Song; Soosung Kang
Journal:  ACS Med Chem Lett       Date:  2022-08-16       Impact factor: 4.632

Review 4.  Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities.

Authors:  Yankai Wen; Joeri Lambrecht; Cynthia Ju; Frank Tacke
Journal:  Cell Mol Immunol       Date:  2020-10-12       Impact factor: 11.530

Review 5.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

6.  IFN Regulatory Factor 4 Controls Post-ischemic Inflammation and Prevents Chronic Kidney Disease.

Authors:  Georg Lorenz; Foteini Moschovaki-Filippidou; Vivian Würf; Philipp Metzger; Stefanie Steiger; Falk Batz; Javier Carbajo-Lozoya; Joanna Koziel; Max Schnurr; Clemens D Cohen; Christoph Schmaderer; Hans-Joachim Anders; Maja Lindenmeyer; Maciej Lech
Journal:  Front Immunol       Date:  2019-10-01       Impact factor: 7.561

Review 7.  Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases.

Authors:  Daphne van der Heide; Ralf Weiskirchen; Ruchi Bansal
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

8.  Splenectomy improves liver fibrosis via tumor necrosis factor superfamily 14 (LIGHT) through the JNK/TGF-β1 signaling pathway.

Authors:  Qing-Shan Liang; Jian-Gang Xie; ChaoPing Yu; ZhuSheng Feng; JingChang Ma; Yuan Zhang; Dong Wang; JianGuo Lu; Ran Zhuang; Jikai Yin
Journal:  Exp Mol Med       Date:  2021-03-03       Impact factor: 8.718

9.  Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis.

Authors:  Alexander Queck; Hannah Bode; Frank E Uschner; Maximilian J Brol; Christiana Graf; Martin Schulz; Christian Jansen; Michael Praktiknjo; Robert Schierwagen; Sabine Klein; Christian Trautwein; Hermann E Wasmuth; Marie-Luise Berres; Jonel Trebicka; Jennifer Lehmann
Journal:  Front Immunol       Date:  2020-03-11       Impact factor: 7.561

Review 10.  Is the Macrophage Phenotype Determinant for Fibrosis Development?

Authors:  Lluis Lis-López; Cristina Bauset; Marta Seco-Cervera; Jesús Cosín-Roger
Journal:  Biomedicines       Date:  2021-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.